General information on Anti-2019-nCoV(S1)-3 antibody
Proteogenix has developed neutralizing antibodies against SARS-COV-2. This antibody is an IgG isotype, especially targeting the S1 part of the Spike protein on the surface of SARS-CoV-2. This product is a human-origin monoclonal antibody expressed in a mammalian system, which has been validated in binding assays and infection assays. The molecular weight is 150 kDa.
About Spike targeting
The spike protein is a transmembrane viral fusion protein. Spike has a homotrimeric structure and each monomere is composed of two subunits: S1 and S2. The S1 part is carrying the Receptor Binding Domain (RBD), and the S2 part is responsible of the fusion of the virus with the cellular membrane. The RBD Part of S1 is binding the Angiotensin Converting Enzyme 2 (ACE2) in the organism.
About Immunoglobulin G-type
Immunoglobulins G type are the most represented class of antibody in the whole human organism, as they are expressed in the humoral immune response against viral or bacterial expression.
Proteogenix launched a panel of antibodies against SARS-CoV-2 spike and the nucleocapsid. Every of them can recognize specifically SARS-CoV-2 antigens without cross reactivity with other human coronaviruses. Neutralizing antibodies are very promising in antiviral defense against the coronavirus disease 2019 (COVID-19) pandemic. This product is also suitable to realize ELISA, WB, FC, IP, Neut, FuncS, IF, and a large panel of immunological methods. Research use only.
There are no reviews yet.